Myomo Launches Myomo Mobile App
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Myomo announces the launch of the Myomo Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro experience. "For clinicians, the Myomo Mobile App is designed to simplify device configuration and improve visibility into patient use, whether care is delivered in clinic or remotely," said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer. "For patients, the app helps make muscle activity more understandable and encourages confidence through real-time feedback and easy access to training resources." The Myomo Mobile App is now available through the Google Play Store and Apple App Store and supporting user manuals for clinicians, patients, and caregivers are available on the company's website.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYO
Wall Street analysts forecast MYO stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.420
Low
4.00
Averages
5.75
High
10.00
Current: 1.420
Low
4.00
Averages
5.75
High
10.00
About MYO
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Myomo, Inc. Q1 2026 Earnings Call Insights
- Medicare Policy Breakthrough: Myomo's MyoPro has gained reimbursement under a new Medicare Part B benefit category by CMS, opening access to tens of millions of Medicare beneficiaries and removing the largest historical barrier to adoption, thereby laying the groundwork for future growth.
- Revenue Growth Momentum: The company reported $10.1 million in revenue for Q1 2026, reflecting a year-over-year increase, with revenue from recurring patient sources rising from 25% to 49%, showcasing success in reducing customer acquisition costs and diversifying revenue streams.
- International Market Expansion: International revenue increased by 53% year-over-year, while the U.S. O&P channel grew by 79%, indicating enhanced penetration in global markets, particularly through collaboration with Ottobock, which further boosts brand influence and market share.
- Technological Innovation and Cost Control: The newly launched mobile app reduces MyoPro material costs by approximately 10% per user while enhancing user experience, indicating that the company's ongoing investment in technological innovation will help improve operational efficiency and profitability.
See More
Myomo Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Myomo reported a Q1 GAAP EPS of -$0.07, beating expectations by $0.04, with revenue of $10.1 million reflecting a 3.1% year-over-year growth, indicating solid market performance.
- Price Increase: The average selling price (ASP) rose to approximately $58,800, up 9% year-over-year, which, despite a slight decrease in revenue units, demonstrates an increase in product value and revenue generation.
- Customer Growth: The company added 723 patients in Q1, a 7% sequential increase, with the cost per pipeline addition at $2,550, down 16% sequentially, showcasing improved efficiency in customer acquisition.
- Future Outlook: Myomo expects Q2 revenue to range between $10.3 million and $10.8 million, reaffirming full-year revenue guidance of $43 million to $46 million, reflecting strong confidence in future growth.
See More
Myomo, Inc. Reports Strong Q4 2025 Earnings with Strategic Focus
- Significant Revenue Growth: Myomo reported $11.4 million in revenue for Q4 2025, reflecting a 26% increase over 2024, with full-year revenue reaching $40.9 million, showcasing the company's success in direct-to-patient marketing and recurring revenue sources.
- Record Orders: The company received 241 MyoPro orders in the quarter, a 5% increase from Q3, indicating not only rising product demand but also successful penetration in the O&P channel and international markets.
- Strategic Partnership Expansion: The new multistate agreement with Elevance Health covers 45 million lives, marking a significant advancement in payer contracts that is expected to support future revenue growth.
- Cautious Future Outlook: Management expects Q1 2026 revenue in the range of $9 million to $9.5 million and sets a full-year target of $43 million to $46 million, reflecting a cautious stance towards market uncertainties while planning to improve gross margins through controlled operating expenses.
See More
Myomo Q4 Earnings Report Analysis
- Disappointing Earnings: Myomo reported a Q4 non-GAAP EPS of -$0.37, missing expectations by $0.28, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Slight Revenue Decline: The company's Q4 revenue of $11.4 million represents a 5.6% year-over-year decline, although it beat expectations by $1 million, the revenue drop reflects weak market demand, potentially affecting future growth prospects.
- Deteriorating Adjusted EBITDA: The adjusted EBITDA for Q4 2025 was -$1.9 million, a significant decline from $0.2 million in Q4 2024, with a full-year adjusted EBITDA of -$11.5 million compared to -$5.1 million in 2024, indicating a decrease in operational efficiency.
- Tight Cash Flow Situation: As of December 31, 2025, the company had $18.4 million in cash and cash equivalents, with Q4 operating cash flow at -$1.1 million, a sharp decline from $3.4 million generated in Q4 2024, highlighting liquidity pressures faced by the company.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Myomo, Inc. Q1 2026 Earnings Call Insights
- Medicare Policy Breakthrough: Myomo's MyoPro has gained reimbursement under a new Medicare Part B benefit category by CMS, opening access to tens of millions of Medicare beneficiaries and removing the largest historical barrier to adoption, thereby laying the groundwork for future growth.
- Revenue Growth Momentum: The company reported $10.1 million in revenue for Q1 2026, reflecting a year-over-year increase, with revenue from recurring patient sources rising from 25% to 49%, showcasing success in reducing customer acquisition costs and diversifying revenue streams.
- International Market Expansion: International revenue increased by 53% year-over-year, while the U.S. O&P channel grew by 79%, indicating enhanced penetration in global markets, particularly through collaboration with Ottobock, which further boosts brand influence and market share.
- Technological Innovation and Cost Control: The newly launched mobile app reduces MyoPro material costs by approximately 10% per user while enhancing user experience, indicating that the company's ongoing investment in technological innovation will help improve operational efficiency and profitability.
See More
Myomo Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Myomo reported a Q1 GAAP EPS of -$0.07, beating expectations by $0.04, with revenue of $10.1 million reflecting a 3.1% year-over-year growth, indicating solid market performance.
- Price Increase: The average selling price (ASP) rose to approximately $58,800, up 9% year-over-year, which, despite a slight decrease in revenue units, demonstrates an increase in product value and revenue generation.
- Customer Growth: The company added 723 patients in Q1, a 7% sequential increase, with the cost per pipeline addition at $2,550, down 16% sequentially, showcasing improved efficiency in customer acquisition.
- Future Outlook: Myomo expects Q2 revenue to range between $10.3 million and $10.8 million, reaffirming full-year revenue guidance of $43 million to $46 million, reflecting strong confidence in future growth.
See More
Myomo, Inc. Reports Strong Q4 2025 Earnings with Strategic Focus
- Significant Revenue Growth: Myomo reported $11.4 million in revenue for Q4 2025, reflecting a 26% increase over 2024, with full-year revenue reaching $40.9 million, showcasing the company's success in direct-to-patient marketing and recurring revenue sources.
- Record Orders: The company received 241 MyoPro orders in the quarter, a 5% increase from Q3, indicating not only rising product demand but also successful penetration in the O&P channel and international markets.
- Strategic Partnership Expansion: The new multistate agreement with Elevance Health covers 45 million lives, marking a significant advancement in payer contracts that is expected to support future revenue growth.
- Cautious Future Outlook: Management expects Q1 2026 revenue in the range of $9 million to $9.5 million and sets a full-year target of $43 million to $46 million, reflecting a cautious stance towards market uncertainties while planning to improve gross margins through controlled operating expenses.
See More
Myomo Q4 Earnings Report Analysis
- Disappointing Earnings: Myomo reported a Q4 non-GAAP EPS of -$0.37, missing expectations by $0.28, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Slight Revenue Decline: The company's Q4 revenue of $11.4 million represents a 5.6% year-over-year decline, although it beat expectations by $1 million, the revenue drop reflects weak market demand, potentially affecting future growth prospects.
- Deteriorating Adjusted EBITDA: The adjusted EBITDA for Q4 2025 was -$1.9 million, a significant decline from $0.2 million in Q4 2024, with a full-year adjusted EBITDA of -$11.5 million compared to -$5.1 million in 2024, indicating a decrease in operational efficiency.
- Tight Cash Flow Situation: As of December 31, 2025, the company had $18.4 million in cash and cash equivalents, with Q4 operating cash flow at -$1.1 million, a sharp decline from $3.4 million generated in Q4 2024, highlighting liquidity pressures faced by the company.
See More
